Resmed Inc. · NYSE:RMD
Resmed — Q2 2023 Earnings Presentation
17 slides from Resmed's earnings presentation, Jan 26, 2023
Slide 1: Q2 FY2023 Earnings
Q2 FY2023 Earnings January 26, 2023
Slide 2: Presentation of financial information & forward-looking statements
Presentation of financial information & forward-looking statements Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc., its subsidiaries, and its legal entities, for the periods indicated. This presentation includes financial information prepa
Slide 3: Our mission is to change 250 million lives in 2025
Our mission is to change 250 million lives in 2025 We're proud to offer digital and connected health solutions that help those with sleep apnea, COPD, and other respiratory diseases live happier, healthier lives in the comfort of home or care setting of their choice During the last 12 months, we cha
Slide 4: ResMed | The global leader in connected and digital health
ResMed | The global leader in connected and digital health Key Statistics1 Headquarters San Diego, CA 11% 11% Founded 1989 Revenue Revenue LTM 2Q23 revenue $3.8B by business 53% 30% by region 36% LTM 2Q23 LTM 2Q23 59% Listed (NYSE, ASX) 1995, RMD Market cap ~$35B Countries served 140+ Devices U.
Slide 5: ResMed 2025: a patient-centric, digitally-enabled strategy
ResMed 2025: a patient-centric, digitally-enabled strategy 250 million lives improved in out-of-hospital healthcare in 2025! Purpose Empower people to live happier, healthier, and higher quality lives in the comfort of their home Growth Focus Global health epidemics in sleep apnea, COPD, other major
Slide 6: Priorities that guide our daily focus
Priorities that guide our daily focus Our triple aim: I. Slow chronic Grow and differentiate Deliver world-leading Build the world's best disease progression our core sleep apnea, medical devices and software solutions COPD, and asthma digital health technology network for healthcare II. Reduce over
Slide 7: Financial Results
Financial Results
Slide 8: Q2 FY23 financial results
Q2 FY23 financial results Revenue by Business Q2 FY23 11% Devices Revenue ($M) Non-GAAP Operating Non-GAAP EPS Income ($M) 53% Masks and other $1,033.7 36% OOH SaaS $305.5 $1.66 $894.9 $1.70 $267.7 $1.50 $1.47 $1.30 Revenue by Region $1.10 Q2 FY23 $0.90 U.S., Canada, $0.70 11% and Latin $0.50 Americ
Slide 9: Solid balance sheet
Solid balance sheet Operating Cash Flow ($M) Capital Expenditures ($M) Free Cash Flow ($M) $883.9 $787.9 Total debt outstanding $1,801M Less: Cash & cash equiv. $253M $577.0 $465.0 $133.5 $370.2 $112.0 Net Debt $1,547M $96.0 $236.7 Unused borrowing capacity $390M LTM 2Q21 LTM 2Q22 LTM 2Q23 LTM 2Q21
Slide 10: Track record of strong financial returns for shareholders
Track record of strong financial returns for shareholders (Financial data as of December 31, 2022) Revenue ($B) Non-GAAP Operating Income ($M) Non-GAAP EPS 11% CAGR 15% CAGR 14% CAGR $3.8 $1,121 $5.98 $2.2 $548 $3.14 LTM 2Q18 LTM 1Q23 LTM 2Q18 LTM 2Q23 LTM 2Q18 LTM 2Q23 Total shareholder return, TSR
Slide 11: Strategic capital allocation framework
Strategic capital allocation framework Strategic Growth Capital deployed over last 3 years • Reinvest in product development for Priorities (through December 31, 2022) Reinvest for high-return organic growth growth • 7-8% of revenue invested in R&D 27% • Actively evaluate potential acquisitions 30%
Slide 12: Driving long-term shareholder value
Driving long-term shareholder value Growth & Innovation Market Dynamics Financial Results • Global leader in digital health for • Underpenetrated markets in sleep • Historical revenue and profit growth sleep and respiratory care and COPD • Recurring revenue • Long-term growth opportunities • Healthc
Slide 13: Contact Investor Relations
Contact Investor Relations Phone: (858) 836-5971 Email: investorrelations@resmed.com Website: investor.resmed.com
Slide 14: Appendix
APPENDIX
Slide 15: Reconciliation of non-GAAP financial measures
Reconciliation of non-GAAP financial measures The measures “non-GAAP gross profit” and “non-GAAP gross margin” excludes amortization expense from acquired intangibles related to cost of sales and are reconciled below: (Unaudited; $ in thousands, except for per share amounts) Three Months Ended Six M
Slide 16: Reconciliation of non-GAAP financial measures, cont'd
Reconciliation of non-GAAP financial measures, cont’d The measure “non-GAAP income from operations” is reconciled with GAAP income from operations below: (Unaudited; $ in thousands, except for per share amounts) Three Months Ended Six Months Ended December 31, December 31, December 31, December 31,
Slide 17: Reconciliation of non-GAAP financial measures, cont'd
Reconciliation of non-GAAP financial measures, cont’d The measure “non-GAAP net income” and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below: (Unaudited; $ in thousands, except for per share amounts) Three Months Ended S